BCX.WAR Bioceltix S.A.
- Market cap
- PLN 392M
- P/E
- -
- P/B
- 6.34x
- ROE
- -34.4%
- Dividend yield
- -
- Fundamental score
- 1.4/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BCX.WAR undervalued?
Graham numberThe Graham number of Bioceltix S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bioceltix S.A. fundamental analysis
6 of 21 checks passedROE 0/2
Low return on equity (-34.4%), below 10%.
ROA 0/1
Return on assets (-32.7%) is below the industry median (-18.6%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (7.7%) is above the industry median (2.6%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (0.3%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 2/2
Cash covers 2.5 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (6.5x) is above the industry median (3.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Bioceltix S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bioceltix S.A.
Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project…
Full company profileBioceltix S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bioceltix S.A. annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 9.20K | 1.50K | 10.8K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.81M | -3.48M | -3.87M | -377K | -445K | -1.04M | -574K | -680K | -708K |
| Operating Income | -1.92M | -3.78M | -3.99M | -6.21M | -9.67M | -15.8M | -18.8M | -17.3M | -23.3M |
| EBITDA | -754K | -1.53M | -2.13M | -3.95M | -8.49M | -13.2M | -14.0M | -16.6M | -22.6M |
| Net Income | -776K | -1.60M | -2.35M | -4.40M | -8.92M | -13.7M | -14.9M | -15.2M | -21.5M |
| EPS | -0.24 | -0.49 | -0.95 | -1.39 | -2.67 | -3.49 | -3.28 | -3.03 | -3.89 |
| Balance Sheet | |||||||||
| Total Assets | 3.30M | 3.23M | 4.80M | 8.20M | 5.99M | 12.7M | 41.9M | 75.6M | 65.7M |
| Total Liabilities | 1.73M | 1.32M | 1.48M | 2.20M | 2.50M | 2.27M | 3.44M | 2.36M | 3.20M |
| Shareholders' Equity | 1.57M | 1.91M | 3.32M | 6.00M | 5.15M | 10.5M | 38.4M | 73.3M | 62.5M |
| Cash & Short-term Investments | 1.57M | 1.10M | 3.20M | 6.05M | 4.12M | 9.31M | 33.6M | 68.4M | 56.8M |
| Total Debt | - | 165K | 104K | 531K | 294K | 175K | 824K | 315K | 171K |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.79M | -1.67M | -1.51M | -4.04M | -7.91M | -14.7M | -17.7M | -12.1M | -17.5M |
| Capital Expenditure | 523K | 180K | 13.9K | 5.98K | 352K | 458K | 243K | 1.97M | 5.31M |
| Free Cash Flow | -2.31M | -1.85M | -1.53M | -4.05M | -8.26M | -15.2M | -18.0M | -14.1M | -22.8M |
| Ratios | |||||||||
| ROE | -49.3% | -83.8% | -70.7% | -73.3% | -173.2% | -130.8% | -38.8% | -20.7% | -34.4% |
| ROA | -23.5% | -49.4% | -48.9% | -53.7% | -149.0% | -107.5% | -35.6% | -20.0% | -32.7% |
| Net Profit Margin | -8,429.2% | -106,422.5% | -21,747.7% | - | - | - | - | - | - |
| Debt to Equity | - | 0.09x | 0.03x | 0.09x | 0.06x | 0.02x | 0.02x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bioceltix S.A. dividends
Bioceltix S.A. has not paid dividends in the last 8 fiscal years.
Who owns Bioceltix S.A.
- Insiders 15.12%
- Institutions 28.83%
- Public & others 56.05%
- Shares outstanding 5.53M
- Free float 4.44M
Bioceltix S.A. company profile
- Company name
- Bioceltix S.A.
- Ticker
- BCX.WAR
- ISIN
- PLBCLTX00019
- Exchange
- Warsaw Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 49
- Fiscal year end
- December
- Address
- bud. III, Wroclaw, Poland, 51-317
- Phone
- 48 534 37 38 08
- Website
- bioceltix.com
About Bioceltix S.A.
Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermatitis in dogs. The company was founded in 2016 and is headquartered in Wroclaw, Poland.
Bioceltix S.A. management
10- Mr. Lukasz BzdzionCEO & President of the Management Board
- Dr. Pawel Wielgus Eng., Ph.D.Member of the Management Board
- Andrij WlachChief Financial Officer
- Mr. Grzegorz OstropolskiChief Operating Officer
- Mr. Lahoud ToumaDirector of Technology
- Mr. Jakub WacekLegal Counsel & General Counsel
- Dr. Patryk Reniewicz Ph.D.Head of R&D and Leader of the In Vitro Diagnostics Development Team
- Ms. Agnieszka KielczykowskaHead of Procurement & Supply
- Ms. Anna Olko-ChudyHead of the Management Office & Tissue Coordinator
- Ms. Katarzyna WroblewskaHead of Quality Assurance